Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)

Sanjay Kalra, Stephen Atkin, Antonio Cervera, Ashok Kumar Das, Orgur Demir, Tevfik Demir, M. Fariduddin, Khoa Tuan Vo, Bon Jeong Ku, Ajay Kumar, Zafar A. Latif, Rachid Malek, Bien J. Matawaran, Roopa Mehta, Nam Quang Tran, Araceli Panelo, Sundeep Ruder, Joel Rodriquez Saldana, Khalid A. Shaikh, Amit ShakyaDina Shrestha, A. G. Unnikrishnan

Research output: Contribution to journalArticle


Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAdvances in Therapy
Publication statusAccepted/In press - 23 May 2018



  • Co-formulation
  • Consensus
  • Hypoglycemia
  • IDegAsp

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Kalra, S., Atkin, S., Cervera, A., Das, A. K., Demir, O., Demir, T., Fariduddin, M., Vo, K. T., Ku, B. J., Kumar, A., Latif, Z. A., Malek, R., Matawaran, B. J., Mehta, R., Tran, N. Q., Panelo, A., Ruder, S., Saldana, J. R., Shaikh, K. A., ... Unnikrishnan, A. G. (Accepted/In press). Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). Advances in Therapy, 1-9.